Moderna Inc. (MRNA)
Health Care11 articles
Price chart
Moderna Inc. (MRNA) overview
Moderna is a biotech pioneering mRNA vaccines and therapeutics. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Moderna Inc. trades on the NasdaqGS under the ticker symbol MRNA. As of the most recent market data, the stock was priced around $61.82, down 2.11% on the session, giving Moderna Inc. a market capitalization of roughly $24.53B.
Over the past 52 weeks, MRNA has traded between $22.28 and $85.60.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MRNA
As one of the larger companies in the Health Care sector, Moderna Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch MRNA for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest MRNA news
Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.
Read More: Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
In FY 2025, Moderna (MRNA) reported revenue exceeding $1.9 billion, a 40% decrease from the prior year, alongside a net loss of approximately $2.8 billion. The company's debt-to-equity ratio was about 0.2x, and free cash flow was nearly $2.1 billion negative. In comparison, Recursion Pharmaceuticals (RXRX) generated approximately $74.7 million in revenue, marking a 27% year-over-year increase, but recorded a net loss of nearly $645 million. Its debt-to-equity ratio stood at around 0.1x, with free cash flow of about negative $378 million, indicating significant investment in its infrastructure.
Read More: Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) and ON Semiconductor (ON) were highlighted among stocks making significant midday moves. Although the article mentions several companies, specific data points, metrics, or trading volumes are not provided regarding these stock movements. Such notable movements can impact investor sentiment and potential trading strategies. Without verifiable events or figures, the overall market implications remain unclear.
Read More: Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
A key FDA advisory panel has unanimously recommended Moderna's (MRNA) mRNA flu vaccine, marking the first of its kind since 2023. This recommendation is significant as it could pave the way for regulatory approval, enhancing Moderna's portfolio and potentially impacting market positioning against competitors. The vaccine is designed specifically for older adults, addressing a critical healthcare need. The panel's endorsement follows discussions regarding the vaccine's efficacy and safety, which may influence investor sentiment in the biopharmaceutical sector.
Read More: Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
The FDA advisory panel voted unanimously to approve Moderna's (MRNA) mRNA flu vaccine for older adults. This decision may impact the market by potentially increasing demand for Moderna's vaccine offerings. The mRNA flu vaccine is expected to enhance B cell response breadth in humans, a factor that could improve public health outcomes. The approval comes after prior controversies surrounding the vaccine's deployment, adding weight to the FDA's endorsement.
Read More: Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) experienced significant stock movement following news of a peace deal in Iran, which positively influenced market sentiment. This development contributed to a rise in the Dow Jones Industrial Average, further supported by bullish trends in AI stocks. The market is observing a shift in trading volumes, but specific numbers were not detailed. Overall, the implications of the Iran agreement on broader market conditions may indicate increased investor confidence.
Read More: Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
On June 15, Moderna (MRNA) filed Form 144, a document indicating the intention to sell shares of its common stock. This filing reflects potential insider selling, which can impact investor sentiment and market perceptions. Understanding the volume and timing of these sales is crucial for assessing the company's stock performance. The details of shares sold or the significance of this transaction will be closely monitored by investors for any potential effects on MRNA's market behavior.
Read More: Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
The US FDA announced it will hold a meeting with an expert committee to review the flu vaccine developed by Moderna (MRNA). This meeting is crucial as it will assess the vaccine's efficacy and safety. Given the increasing interest in flu vaccinations, particularly in the context of ongoing health concerns, this evaluation may impact market perception of Moderna's future revenues. The outcome of the review could influence both Moderna's stock performance and broader market trends in the biotech sector.
Read More: Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) is currently under scrutiny regarding its profitability as the company's revenue streams face challenges. The latest reports indicate a significant decrease in demand for its COVID-19 vaccine, leading to a projected revenue drop of 70% for 2023 compared to 2022. Given these developments, experts are closely monitoring MRNA's financial stability and operational adjustments. The ongoing analysis could impact the biotech sector as investors evaluate the company's future prospects.
Read More: Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Several stocks, including Moderna (MRNA), Lumentum, Intel, and monday.com, are experiencing notable movements in premarket trading. However, concrete data points such as trading volumes or percentage changes have not been reported in this article. The market impact of these movements remains unclear due to the lack of specific figures or insights into the reasons behind the fluctuations. Monitoring these stocks could provide insights into broader market trends and investor sentiment.
Read More: Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Following the World Health Organization's announcement of a hantavirus outbreak on May 2, several pharmaceutical stocks, including Moderna (MRNA), experienced significant gains. Moderna's shares increased by 7% in premarket trading as the company is conducting preclinical research on the hantavirus. Inovio Pharmaceuticals reported a 13% rise, while Emergent Biosolutions and Novavax gained 4% and 3%, respectively. Analysts from Evercore ISI suggested that any revenue potential for Moderna related to hantavirus is unlikely, viewing stock movements as sentiment-driven rather than fundamentally driven.
Read More: Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus ConcernsMore Health Care stocks
Frequently asked questions
Is Moderna Inc. in the S&P 500?
Yes. Moderna Inc. (MRNA) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is MRNA in?
Moderna Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest MRNA news?
This page collects recent Moderna Inc. (MRNA) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Moderna Inc.'s stock price?
As of the most recent market data, Moderna Inc. (MRNA) traded at approximately $61.82. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Moderna Inc.'s market cap?
Moderna Inc. has a market capitalization of roughly $24.53B, based on its most recent share price and shares outstanding.